IL17A and psoriasis: Along this line, systemic treatment of psoriasis with methotrexate [29] and anti-inflammatory biologics has been suggested to reduce the risk of CVD [30,31,32], although controversy remains and the role of, e.g., IL-17 in atherosclerotic CVD is unclear [3,33,34,35,36].